BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Unal S, Masterton R, Goossens H. Bacteraemia in Europe—antimicrobial susceptibility data from the MYSTIC surveillance programme. International Journal of Antimicrobial Agents 2004;23:155-63. [DOI: 10.1016/j.ijantimicag.2003.07.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). Diagnostic Microbiology and Infectious Disease 2006;54:249-57. [DOI: 10.1016/j.diagmicrobio.2005.10.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
2 Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J Chemother 2005;17:459-69. [PMID: 16323433 DOI: 10.1179/joc.2005.17.5.459] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
3 Khan FY, Elshafie SS, Almaslamani M, Abu-Khattab M, El Hiday AH, Errayes M, Almaslamani E. Epidemiology of bacteraemia in Hamad general hospital, Qatar: a one year hospital-based study. Travel Med Infect Dis 2010;8:377-87. [PMID: 21074495 DOI: 10.1016/j.tmaid.2010.10.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
4 Krueger WA, Bulitta J, Kinzig-Schippers M, Landersdorfer C, Holzgrabe U, Naber KG, Drusano GL, Sörgel F. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005;49:1881-9. [PMID: 15855510 DOI: 10.1128/AAC.49.5.1881-1889.2005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
5 Scanvic A, Courdavault L, Sollet JP, Le Turdu F. [Interest of real-time PCR Xpert MRSA/SA on GeneXpert(®) DX System in the investigation of staphylococcal bacteremia]. Pathol Biol (Paris) 2011;59:67-72. [PMID: 20832193 DOI: 10.1016/j.patbio.2010.07.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
6 Fabian TC, File TM, Embil JM, Krige JE, Klein S, Rose A, Melnick D, Soto NE. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt) 2005;6:269-82. [PMID: 16201937 DOI: 10.1089/sur.2005.6.269] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
7 Hayakawa M, Ito Y, Fujita I, Iseki K, Gando S. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study. ASAIO J 2006;52:398-403. [PMID: 16883119 DOI: 10.1097/0.1mat.0000225268.28044.ae] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
8 Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:479-87. [PMID: 15673721 DOI: 10.1128/AAC.49.2.479-487.2005] [Cited by in Crossref: 257] [Cited by in F6Publishing: 104] [Article Influence: 15.1] [Reference Citation Analysis]
9 Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin Microbiol Infect 2005;11:256-80. [PMID: 15760423 DOI: 10.1111/j.1469-0691.2005.01131.x] [Cited by in Crossref: 242] [Cited by in F6Publishing: 203] [Article Influence: 14.2] [Reference Citation Analysis]
10 Unal S, Garcia-Rodriguez JA. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 2005;53:265-71. [PMID: 16360550 DOI: 10.1016/j.diagmicrobio.2005.10.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
11 Xiao YH, Wang J, Li Y; MOH National Antimicrobial Resistance Investigation Net. Bacterial resistance surveillance in China: a report from Mohnarin 2004-2005. Eur J Clin Microbiol Infect Dis 2008;27:697-708. [PMID: 18563461 DOI: 10.1007/s10096-008-0494-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
12 Poole K. Pseudomonas aeruginosa. In: White DG, Alekshun MN, Mcdermott PF, editors. Frontiers in Antimicrobial Resistance. Washington: ASM Press; 2005. pp. 355-66. [DOI: 10.1128/9781555817572.ch26] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ruimy R, Dos-Santos M, Raskine L, Bert F, Masson R, Elbaz S, Bonnal C, Lucet JC, Lefort A, Fantin B, Wolff M, Hornstein M, Andremont A. Accuracy and potential usefulness of triplex real-time PCR for improving antibiotic treatment of patients with blood cultures showing clustered gram-positive cocci on direct smears. J Clin Microbiol 2008;46:2045-51. [PMID: 18417663 DOI: 10.1128/JCM.02250-07] [Cited by in Crossref: 41] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
14 Korten V, Ulusoy S, Zarakolu P, Mete B. Antibiotic resistance surveillance over a 4-year period (2000–2003) in Turkey: results of the MYSTIC Program. Diagnostic Microbiology and Infectious Disease 2007;59:453-7. [DOI: 10.1016/j.diagmicrobio.2007.06.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
15 Al-Hasan MN, Wilson JW, Lahr BD, Eckel-Passow JE, Baddour LM. Incidence of Pseudomonas aeruginosa bacteremia: a population-based study. Am J Med 2008;121:702-8. [PMID: 18691484 DOI: 10.1016/j.amjmed.2008.03.029] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
16 Drago L, De Vecchi E, Nicola L, Legnani D, Lombardi A, Gismondo MR. In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or beta-lactams against extended-spectrum beta-lactamase-producing Escherichia coli. J Chemother 2005;17:46-53. [PMID: 15828443 DOI: 10.1179/joc.2005.17.1.46] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
17 Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012;67:2793-803. [PMID: 22915465 DOI: 10.1093/jac/dks301] [Cited by in Crossref: 227] [Cited by in F6Publishing: 207] [Article Influence: 22.7] [Reference Citation Analysis]
18 Webber MA, Piddock LJV. Antibiotic Resistance in Escherichia coli. In: White DG, Alekshun MN, Mcdermott PF, editors. Frontiers in Antimicrobial Resistance. Washington: ASM Press; 2005. pp. 374-86. [DOI: 10.1128/9781555817572.ch28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Parkins MD, Gregson DB, Pitout JD, Ross T, Laupland KB. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection. 2010;38:25-32. [PMID: 20012908 DOI: 10.1007/s15010-009-9145-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
20 Jones RN, Mendes C, Turner PJ, Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis 2005;53:247-56. [PMID: 16360548 DOI: 10.1016/j.diagmicrobio.2005.10.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]